Genocea Biosciences Inc Quick Ratio (GNCA) starting from the first quarter 2022 to first quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Genocea Biosciences Inc   (NASDAQ: GNCA)

Genocea Biosciences Inc 's Quick Ratio

GNCA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the first quarter 2022, Quick Ratio deteriorated to 1.12 below Genocea Biosciences Inc 's average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 177 other companies have achieved higher Quick Ratio than Genocea Biosciences Inc in first quarter 2022. While Quick Ratio total ranking in the first quarter 2022 has deteriorated compared to the prior quarter from 1028 to 2591.

Explain Quick Ratio?
How much Cash & cash equivalents GNCA´s has?
What are GNCA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GNCA Quick Ratio (Mar 31 2022)
Q1		 (Dec 31 2021)
Q4		 (Sep 30 2021)
Q3		 (Jun 30 2021)
Q2		 (Mar 31 2021)
Q1
Y / Y Current Liabilities Change 57.83 % -25.25 % -38.26 % -31.09 % -22.1 %
Y / Y Cash & cash equivalent Change -69.51 % -53.43 % -44.18 % 173.2 % 149.1 %
Quick Ratio MRQ 1.12 1.99 3.33 4.07 5.78
GNCA's Total Ranking # 2591 # 1028 # 375 # 1153 # 1181
Seq. Current Liabilities Change -3.5 % 27.06 % -0.86 % 29.83 % -54.29 %
Seq. Cash & cash equivalent Change -45.79 % -24.05 % -19.03 % -8.53 % -17.22 %



Quick Ratio first quarter 2022 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 178
Healthcare Sector # 941
Overall Market # 2591


Quick Ratio Statistics
High Average Low
77.11 13.33 1.03
(Jun 30 2016)   (Jun 30 2020)




Financial Statements
Genocea Biosciences Inc 's Current Liabilities $ 18 Millions Visit GNCA's Balance sheet
Genocea Biosciences Inc 's Cash & cash equivalent $ 20 Millions Visit GNCA's Balance sheet
Source of GNCA's Sales Visit GNCA's Sales by Geography


Cumulative Genocea Biosciences Inc 's Quick Ratio

GNCA's Quick Ratio for the trailling 12 Months

GNCA Quick Ratio

 (Mar 31 2022)
12 Months		 (Dec 31 2021)
12 Months		 (Sep 30 2021)
12 Months		 (Jun 30 2021)
12 Months		 (Mar 31 2021)
12 Months
Y / Y Current Liabilities TTM Growth -18.97 % -29.83 % -0.5 % 40.21 % 94.52 %
Y / Y Cash & cash equivalent TTM Growth -34.81 % -1.63 % 44.65 % 117.02 % 48.61 %
Quick Ratio TTM 2.51 3.56 3.87 3.91 3.13
Total Ranking TTM # 5654 # 690 # 828 # 816 # 5639
Seq. Current Liabilities TTM Growth 11.08 % -9.57 % -12.14 % -8.18 % -3.81 %
Seq. Cash & cash equivalent TTM Growth -21.6 % -16.71 % -13.18 % 14.98 % 18.3 %

Quick ratio ranking by company, industry and sector >> Back to GNCA Financial Strength Comparisons >> Go to Compare GNCA Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q1 2022 to $18.03 millions, cumulative Quick Ratio decreased to 2.51 below the Genocea Biosciences Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 193 other companies have achieved higher Quick Ratio than Genocea Biosciences Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2021 from 690 to 5654.

Explain Quick Ratio?
How much Cash & cash equivalents GNCA´s has?
What are GNCA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 194
Healthcare Sector # 1201
Within the Market # 5654


trailing twelve months Quick Ratio Statistics
High Average Low
13.29 4.22 2.22
(Dec 31 2016)   (Dec 31 2017)




Companies with similar Quick Ratio in the quarter ending Mar 31 2022, within Biotechnology & Pharmaceuticals Industry Quick RatioMar 31 2022 MRQ Cash & cash equivalentMar 31 2022 MRQ Current Liabilities
Atara Biotherapeutics Inc   2.97 $ 301.811  Millions$ 101.562  Millions
Qiagen N v   2.90 $ 1,418.266  Millions$ 488.286  Millions
Greenlight Biosciences Holdings Pbc  2.82 $ 83.223  Millions$ 29.524  Millions
Denali Therapeutics Inc   2.81 $ 957.522  Millions$ 341.240  Millions
La Jolla Pharmaceutical Company  2.78 $ 44.559  Millions$ 16.048  Millions
Sangamo Therapeutics Inc   2.68 $ 317.796  Millions$ 118.526  Millions
Polarityte Inc   2.66 $ 18.723  Millions$ 7.045  Millions
Argenx Se  2.65 $ 800.740  Millions$ 302.277  Millions
Applied Genetic Technologies Corporation  2.63 $ 67.849  Millions$ 25.809  Millions
Neurocrine Biosciences Inc   2.62 $ 664.900  Millions$ 253.500  Millions
Brainstorm Cell Therapeutics inc   2.50 $ 18.397  Millions$ 7.372  Millions
Quince Therapeutics Inc   2.47 $ 23.960  Millions$ 9.710  Millions
Apeiron Capital Investment Corp   2.42 $ 0.644  Millions$ 0.267  Millions
Adma Biologics Inc   2.26 $ 69.505  Millions$ 30.770  Millions
Zivo Bioscience Inc   2.24 $ 6.631  Millions$ 2.960  Millions
Vaxart Inc   2.20 $ 24.254  Millions$ 11.035  Millions
Cellectis S a   2.17 $ 104.653  Millions$ 48.131  Millions
Coherus Oncology inc   2.12 $ 325.680  Millions$ 153.748  Millions
Eloxx Pharmaceuticals Inc   2.07 $ 39.768  Millions$ 19.174  Millions
Innate Pharma Sa  2.04 $ 94.332  Millions$ 46.299  Millions
Taysha Gene Therapies Inc   1.99 $ 96.630  Millions$ 48.617  Millions
Nanostring Technologies Inc   1.99 $ 98.457  Millions$ 49.586  Millions
10x Capital Venture Acquisition Corp Iii  1.93 $ 0.672  Millions$ 0.348  Millions
Outlook Therapeutics Inc   1.86 $ 58.424  Millions$ 31.411  Millions
Mink Therapeutics Inc   1.84 $ 34.688  Millions$ 18.834  Millions
Bluebird Bio Inc   1.80 $ 211.588  Millions$ 117.382  Millions
Vir Biotechnology Inc   1.75 $ 1,226.586  Millions$ 702.361  Millions
Meiragtx Holdings Plc  1.74 $ 113.781  Millions$ 65.501  Millions
Mesoblast Limited  1.72 $ 76.760  Millions$ 44.722  Millions
Biocardia Inc   1.71 $ 6.700  Millions$ 3.913  Millions

Date modified: 2026-09-18T13:11:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.